Business Wire

Netmore Partners with Detectronic on Multi-Year Wastewater Management Sensor Deployment

28.8.2025 13:49:00 CEST | Business Wire | Press Release

Share

Netmore Group, the leading network operator for Massive IoT, today announced a partnership with Detectronic, a UK-based environmental and engineering company with a focus on helping utilities and industrial clients prevent flooding and reduce pollution.

Detectronic has begun rolling out more than 90,000 sewer monitors across Yorkshire Water’s wastewater network as part of a major sewer network telemetry program. Over the next five years, 65,000 Pressure Alarm (PAL) sensors and 27,000 LIDoTT Alarms will be installed, creating one of the most comprehensive monitoring networks of its kind in the World. This collaboration will leverage the LoRaWAN network being implemented by Netmore to support Yorkshire Water’s 1.3 million smart meter exchange project within which Netmore is deploying and densifying regional network coverage to satisfy service levels required for Yorkshire Water to achieve targeted service improvements.

This same regional advanced metering infrastructure (AMI) network, deployed and managed by Netmore, will be used to connect Detectronic’s PAL sensor, the company’s first LoRaWAN-enabled product designed as a domestic sewer alarm with smart connectivity for residential gullies and shallow chambers. This innovative sensor ensures long-range, battery-operated communication, delivering highly accurate data to support Yorkshire Water’s environmental and operational goals.

“We are excited to partner with Detectronic to help ensure reliable wastewater monitoring that aligns with Yorkshire Water’s commitment to environmental stewardship,” said Vadim Lyu, UK Managing Director at Netmore. “This partnership underscores our dedication to innovation and sustainability in the water industry and provides a powerful example of how a network deployed for an anchor use case like smart metering can be used to support numerous water management applications to meet the evolving needs of utilities and communities.”

Gavin Wagstaff, Product & Data Director at Detectronic, commented: “We’re proud to be selected as a framework partner for Yorkshire Water and to collaborate with Netmore in delivering a robust, scalable, and highly accurate network monitoring infrastructure. The PAL sensor marks the beginning of our roadmap to develop more LoRaWAN-compatible devices that enable long-range communication for battery-operated monitoring solutions.”

Rob Button, Service Delivery Director at Detectronic, added: “Our role in this project goes beyond supply and installation - we’re also responsible for the planned maintenance of all sensors throughout the five-year framework. To support this major contract, we’re expanding our operations and establishing a new base in Yorkshire, creating a range of job opportunities.”

This partnership between Netmore and Detectronic builds on Netmore’s longstanding collaboration with Yorkshire Water, reinforcing a shared commitment to innovative smart water solutions that protect the environment and enhance operational resilience.

About Netmore Group

Netmore Group is the leading global network operator for Massive IoT, powering the world’s most advanced and sustainability-focused solutions for utilities, buildings, cities, and other markets that benefit from sensor-connected environments. With a decade of innovation and leadership in IoT platform development and network operations, Netmore continues to set the standard for IoT excellence. Netmore operates in 18 countries and is backed by Nordic infrastructure investor Polar Structure.

About Detectronic

Detectronic, part of the Adler and Allan Group, is a UK-based environmental and engineering company with a strong track record in helping utilities and industrial clients prevent flooding and reduce pollution. We design and manufacture a wide range of flow and level monitoring solutions for wastewater applications. As a proud UK manufacturer, we combine technical expertise with an analytical and creative approach to problem-solving, delivering high-quality, efficient solutions tailored to our customers’ needs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250828159921/en/

Contacts

Media Contact:
James Gerber
Crackle Communications
+1 508-233-3391
netmore@cracklepr.com

Netmore Contact:
Ken Lynch
VP, Global Marketing
+1 617-877-5393
ken.lynch@netmoregroup.com

Detectronic Contact:
Lyndsey Shaw
Marketing Manager
+44 1282 449 124
lshaw@detectronic.org

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye